Prevention of Noise-Induced Hearing Loss in Primary Education

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorErasmus Medical Center

About this trial

The goal of this randomized controlled trial is to evaluate the effectiveness of the educational program the HoorToren in promoting recreational safe listening behavior among Dutch primary school children in group 7 (aged 10-11 years) and thereby contribute to preventing noise-induced hearing loss. The main objectives are:

* To evaluate the HoorToren's effects on promoting the child's safe listening behavior when using headphones or earbuds. Both safe listening and its psychological determinants will be measured. * To evaluate the HoorToren's effects on parents' perception of their child's safe listening behaviors. The effects on parental behavior promoting or facilitating their child's safe listening behavior, including its psychological determinants, will also be evaluated.

Researchers will compare children who receive lessons from the HoorToren educational program, and their parents (intervention group) with children and their parents who do not receive the lessons (control group) to evaluate the effectiveness of the HoorToren. Outcomes will be assessed using newly developed and validated self-report questionnaires for both children and their parents. Additionally, the child's listening behavior will be measured via a smartphone application installed on the child's phone. Measurements will take place at four time points during the school year.

Eligibility criteria

Qualifiers

Dutch primary school children in group 7 (corresponding to Year 6 in the UK).

Informed consent from legally authorized parent(s) or guardian(s).

Disqualifiers

Children without informed consent from legally authorized parent(s) or guardian(s).

Children who cannot read and write Dutch.

Trial design

Treatments tested in this trial

  • HoorToren educational package

Treatment groups

600 Participants
are divided into 2 treatment groups

Sponsors and collaborators